i agree resourced,
best to defer
its also about time this company started thinking outside the square in terms of generating cashflow as well
id rather hear about the entire batch in cold storage heading to some country for medical tourism use
you know if you have a staph infection that cant be cured by antibiotics and your leg is coming off you can go to Georgia and get treated by bacteriophages
here is some info
http://www.youtube.com/watch?v=2m_8T6wDT-M
http://en.wikipedia.org/wiki/Bacteriophage
"Their use has continued since the end of the Cold War in Georgia and elsewhere in Eastern Europe. Globalyz Biotech is an international joint venture that commercializes bacteriophage treatment and its various applications across the globe. The company has successfully used bacteriophages in administering Phage therapy to patients suffering from bacterial infections, including: Staphylococcus (including MRSA), Streptococcus, Pseudomonas, Salmonella, skin and soft tissue, gastrointestinal, respiratory, and orthopedic infections."
- Forums
- ASX - By Stock
- TIS
- defer us trials until cashflow
defer us trials until cashflow, page-21
Featured News
Add TIS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online